Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,085 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05769010RecruitingPhase 2
HER2-positive or low breast cancer brain metastasis drug study
This Phase 2 study tests SHR-A1811 in people with HER2-positive (or HER2-low) advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and control the cancer in the brain, especially when there was no need for urgent local treatment like radiation or surgery.
Zhengzhou, HenanAges 18–75 - NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Elche, AlicanteAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT07341737RecruitingPhase 1/Phase 2
SL-28 for advanced solid tumors that haven’t responded to treatment
This trial tests a new drug, SL-28, for people with advanced solid tumors that haven’t responded to or cannot be treated with standard therapies. It aims to find a safe dose and see if the drug can help shrink or slow the growth of your cancer.
Sydney, New South WalesAges 18 years+ - NCT05868226RecruitingPhase 1/Phase 2
Personalized cancer treatment study for advanced solid tumors
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Birmingham, AlabamaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT04150042RecruitingPhase 1
Test of chemotherapy plus your own stem cells for metastatic cancer
This Phase 1 trial tests a treatment approach using standard chemotherapy along with stem cells taken from you to treat metastatic pancreatic or breast cancer. It is mainly designed to check safety and find the best way to give the treatment, and it may offer an option for people whose cancer has spread.
Boston, MassachusettsAges 18 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06125080RecruitingPhase 2
Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Wuhan, HubeiAges 18–70 - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06278870RecruitingPhase 3
New drug combo vs standard for HER2+ advanced breast cancer
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
Guangzhou, GuangdongAges 18–75 - NCT07766018RecruitingPhase 2
Elacestrant for advanced or metastatic breast cancer
This trial tests a new hormone therapy pill, elacestrant, for people with a specific type of breast cancer (ER+, HER2-) that has a certain genetic change (ESR1 mutation) and has grown despite previous hormone therapy. The goal is to see if this drug can help control the cancer.
ChibaAges 18 years+ - NCT07753226RecruitingPhase 1
Study of SI-B036 for advanced breast cancer and other solid tumors
This study tests a new drug called SI-B036 for people with advanced breast cancer or other solid tumors that have spread. The goal is to see if the drug is safe and to find the best dose.
Beijing, Beijing MunicipalityAges 18–75 - NCT07729956RecruitingPhase 3
Study of BL-B01D1 plus immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) against a standard chemo/immu-notherapy combination. It is for people with previously untreated, advanced triple-negative breast cancer whose tumors have a protein called PD-L1.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07648914RecruitingPhase 3
BL-B01D1 versus chemotherapy for advanced hormone-receptor-positive breast cancer
This trial tests a new targeted drug called BL-B01D1 against standard chemotherapy in patients with advanced breast cancer that is hormone-receptor-positive (HR+) and HER2-negative, and has stopped responding to hormone treatments. The goal is to see if the new drug works better or has fewer side effects.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06636981RecruitingPhase 2
Combination therapy for advanced triple negative breast cancer
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT06492005RecruitingPhase 2
Study of 9MW2821 for advanced triple-negative breast cancer
This trial tests a new drug, 9MW2821 (sometimes with a PD-1 inhibitor), for people with advanced triple-negative breast cancer. It may be an option if you've already tried standard treatments or haven't started any yet.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07471776RecruitingPhase 2
Predicting ADC treatment response with PET scans in advanced breast cancer
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07413939RecruitingPhase 2/Phase 3
Study of RO7771950 vs tucatinib for HER2-positive breast cancer
This trial tests a new drug, RO7771950, against another drug called tucatinib. Both are given with standard chemotherapy to see which works better for advanced breast cancer that is HER2-positive. People with brain metastases may join.
Huntsville, AlabamaAges 18 years+ - NCT07357597RecruitingPhase 4
Preventing mouth sores during breast or lung cancer treatment
This trial tests whether a steroid mouthwash can prevent mouth sores caused by the drug Datopotamab Deruxtecan (Dato-DXd). It is for people with certain types of advanced breast cancer or lung cancer who are about to start Dato-DXd for the first time.
Tucson, ArizonaAges 18 years+
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,085 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.